The 3 linked references in paper O. Korennova Yu., L. Shukil' V., S. Mal'tsev N., I. Klinyshkov A., N. Leganova M., E. Turusheva A., T. Kropotina V., О. Кореннова Ю., Л. Шукиль В., С. Мальцев Н., И. Клинышков А., Н. Леганова М., Е. Турушева А., Т. Кропотина В. (2016) “Фармакоэкономическое обоснование применения генно-инженерных биологических препаратов в амбулаторных условиях // PHARMACOECONOMIC SUBSTANTIATION OF APPLICATION OF GENETICALLY ENGINEERED BIOLOGICAL AGENTS IN OUT-PATIENT CONDITIONS” / spz:neicon:pharmacoeconomics:y:2016:i:1:p:39-48

  1. Heijde D., Sieper J., Maksymowych W. et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann. Rheum. Dis. 2011; 70: 905-8. DOI:10.1136/ard.2011.151563.
  2. Prevoo M.L., van't Hof M.A., Kuper H.H. et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995 Jan; 38 (1): 44-8. DOI: http:// dx.doi.org/10.1002/art.1780380107.
  3. Salgado E., Maneiro J.R., Carmona L. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and metaanalysis. Ann Rheum Dis. DOI:10.1136/annrheumdis-2012-203116.